28 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
2913296	4	Cardiotonic agents. 1-Methyl-7-(4-pyridyl)-5,6,7,8-tetrahydro-3 (2H)-isoquinolinones and related compounds. Synthesis and activity.	Mitsui Toatsu Chemicals
15887951	29	The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases.	Monash University (Parkville Campus)
10090791	77	Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives.	Tanabe Seiyaku
8254606	55	Cyclic GMP phosphodiesterase inhibitors. 1. The discovery of a novel potent inhibitor, 4-((3,4-(methylenedioxy)benzyl)amino)-6,7,8-trimethoxyquinazoline.	Eisai
2822927	51	Cardiotonic agents. 8. Selective inhibitors of adenosine 3',5'-cyclic phosphate phosphodiesterase III. Elaboration of a five-point model for positive inotropic activity.	Warner-Lambert
2985781	53	A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.	TBA
12824030	67	1,7- and 2,7-naphthyridine derivatives as potent and highly specific PDE5 inhibitors.	Tanabe Seiyaku
11755362	24	Synthesis of 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridine-6-yl)-benzoic acid: a potent and selective phosphodiesterase type 4D inhibitor.	Novartis Pharma
	71	Imidazotriazinone inhibitors of the Ca2+-calmodulin sensitive phosphodiesterase (PDE I)	TBA
16337379	14	Identification of phosphodiesterase-1 and 5 dual inhibitors by a ligand-based virtual screening optimized for lead evolution.	Sumitomo Pharmaceuticals
16275071	26	A new chemical tool for exploring the physiological function of the PDE2 isozyme.	Pfizer
16005625	162	Discovery of hydroxamic acid analogs as dual inhibitors of phosphodiesterase-1 and -5.	Sumitomo Pharmaceuticals
15993055	61	Comparison of different heterocyclic scaffolds as substrate analog PDE5 inhibitors.	Bayer Healthcare
15324877	90	Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 2: Optimization of 5,8-disubstituted derivatives.	Pfizer
15324876	94	Spiroquinazolinones as novel, potent, and selective PDE7 inhibitors. Part 1.	Pfizer
15324874	169	Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.	Pfizer
15149695	24	New substituted triaza-benzo[cd]azulen-9-ones as promising phosphodiesterase-4 inhibitors.	Pfizer
31021628	50	Pharmacokinetics-Driven Optimization of 4(3 H)-Pyrimidinones as Phosphodiesterase Type 5 Inhibitors Leading to TPN171, a Clinical Candidate for the Treatment of Pulmonary Arterial Hypertension.	Chinese Academy of Sciences
10197972	133	1-Arylnaphthalene lignan: a novel scaffold for type 5 phosphodiesterase inhibitor.	Tanabe Seiyaku
30554955	34	Design, synthesis of novel purin-6-one derivatives as phosphodiesterase 2 (PDE2) inhibitors: The neuroprotective and anxiolytic-like effects.	Changzhou University
9873594	44	Aryl sulfonamides as selective PDE4 inhibitors.	Chiroscience
30986068	112	Structure Overhaul Affords a Potent Purine PI3K? Inhibitor with Improved Tolerability.	TBA
25062128	16	Discovery of clinical candidate 1-(4-(3-(4-(1H-benzo[d]imidazole-2-carbonyl)phenoxy)pyrazin-2-yl)piperidin-1-yl)ethanone (AMG 579), a potent, selective, and efficacious inhibitor of phosphodiesterase 10A (PDE10A).	Amgen
6471063	10	Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3 (2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure.	TBA
9379444	54	Selective inhibitors of cyclic AMP-specific phosphodiesterase: heterocycle-condensed purines.	Hokuriku University
8632423	16	Homologs of idoxifene: variation of estrogen receptor binding and calmodulin antagonism with chain length.	Institute of Cancer Research
3585900	10	Cardiotonic agents. 5. 1,2-Dihydro-5-[4-(1H-imidazol-1-yl)phenyl]-6-methyl-2-oxo-3- pyridinecarbonitriles and related compounds. Synthesis and inotropic activity.	TBA
2822926	95	Cardiotonic agents. 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-activity relationships and correlation with in vivo positive inotropic activi	Warner-Lambert